Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

DiaMedica Therapeutics Inc

DMAC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$6.68

▼ -1.04%

Market Cap $360.22M · Vol 71.92K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$360.22M

Small Cap

Div Yield

N/A

EPS Growth

-10.86%

YoY

RSI (14)

48.28

Momentum

Beta

0.96

vs Market

52W High

$10.41

35.83% below

52W Low

$5.14

29.96% above

Volume

71.92K

Avg 73.88K

P/B

7.62

Price-to-book

ROE

N/A

Return on equity

Free Float

56.63%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, DiaMedica Therapeutics Inc (DMAC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DMAC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.04%

-10.09%

+5.03%

-21.69%

YTD

-16.08%

+11.15%

+125.30%

+115.48%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-32,766,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-60.79% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	7.62
P/FCF	N/A
EPS Growth	-10.86%
Outstanding Shares	53.93M

Technical Indicators

50-Day SMA	$6.66
200-Day SMA	$7.19
RSI (14)	48.28
Beta	0.96
52-Week High	$10.41
52-Week Low	$5.14

Volume Today	71.92K
Avg Daily Volume (30D)	73.88K
Relative Volume	0.97x
Volatility (10D)	26.06
Volatility (30D)	40.36
Free Float	56.63%

Analyst Consensus

BUY

Current Price $6.68

Mean Target $17.00

52W Low$5.14 52W High$10.41

Current

Target

$5.14 $10.41

Current Analyst target

+154.49% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SQ3K65

ISINCA25253X2077

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.